StockIQ.techSummit Therapeutics Inc. (SMMT) Stock Analysis
Free AI-powered analysis and research for Summit Therapeutics Inc. stock
Sector: Healthcare
SMMT snapshot
Data as of 3 Nov 2026 close. Updated daily.
Summit Therapeutics Inc. scores 46/100 on StockIQ's model, which reads as mixed signals overall. The price is below its 200-day average and at 23% of its 52-week range, down 11.7% over the past year. Latest reported figures show a profit margin of 0.0% and return on equity of -192.5%.
What is driving the score
- RSI Neutral: +5
- Mixed Trend: -1
- MACD Bullish: +8
- Weak Profit Margin (0.0%): -8
- Low Debt (0.03 D/E): +8
- Strong Liquidity (6.96 Current Ratio): +8
- Negative ROE (-192.5%): -10
- High P/B (19.86): -5
- Below MA200: -4
- Underperforming (-11.7% over 1 year): -5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full SMMT report
Summit Therapeutics Inc. (SMMT) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze SMMT Now →📰 Latest Update
Summit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI Deal
Fri, October 30, 2026 at 9:08 PM UTC 4 min read
Summit Therapeutics (SMMT) has been identified as potentially 46% undervalued following promising developments in its cancer trials and a strategic partnership involving artificial intelligence. This news is significant for investors as it suggests that the company's stock may not fully reflect its growth potential, particularly in the oncology sector. The combination of innovative therapies and technology could enhance SMMT's market position and drive future revenue growth.